Breakpoints

#42 – The Level is in the Details: Beta-lactam Therapeutic Drug Monitoring

Aug 20, 2021
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 2min
2
Betalact Cam Therapeutic Drug Monitoring in the United States
01:52 • 2min
3
The Importance of Pharmacokinetics and Pharmacodynamics in Therapeutic Drug Monitoring
03:33 • 2min
4
PKPD: The Foundation of Dosing Regimens for Drugs
05:16 • 2min
5
The Role of Therapeutic Drug Monitoring in Beta-Lactam PKPD Optimization
07:15 • 2min
6
Beta-Lactam TDM: A Safety Mechanism for Antibiotics
09:32 • 3min
7
Beta Lactams: How Long Do We Have?
12:41 • 2min
8
The Importance of Preclinical Data in Antibiotic Dosing
14:46 • 3min
9
Beta Lactam Exposure in Patients With Bacterial Infections
17:59 • 3min
10
The Relationship Between Preclinical Data and Patient Outcomes
21:02 • 3min
11
The Role of Dose in Infectious Diseases
23:37 • 3min
12
The Role of Time Above the MIC in Pneumonia
26:31 • 4min
13
The Variability of Exposures in Mice
30:52 • 3min
14
The Importance of Intrapation Variability
33:44 • 4min
15
The Safety Concerns With Escalating Doses
37:26 • 2min
16
The Importance of a Robust Exposure Profile
39:45 • 2min
17
The Importance of Dosing Intermittently Versus Continuous Infusion
42:13 • 3min
18
Different Dosing Targets for Different Patients
44:49 • 2min
19
Beta Lactam PKPD Targets in Critically Ill Patients
46:52 • 3min
20
The Benefits of Early TDM for Pharmacists
49:32 • 2min
21
Beta Lactam TDM: A Decentralized Stewardship Model
51:05 • 2min
22
Beta Lactam Therapeutic Drug Monitoring
53:21 • 2min